An individual M&A transaction in which Mitsubishi Tanabe Pharma Corporation's remaining non-controlling interests were acquired through a tender offer and a demand for the sale of shares, making the company a wholly owned subsidiary. The transaction concerns a capital policy and organizational restructuring aimed at bringing Mitsubishi Tanabe Pharma Corporation's pharmaceutical business platform into the group.